Showing 191-200 of 3104 results for "".
Could a Novel Oral Therapy Change How Clinicians Treat Obstructive Sleep Apnea?Insights From the SynAIRgy Trial
https://practicalneurology.com/diseases-diagnoses/sleep/could-a-novel-oral-therapy-change-how-clinicians-treat-obstructive-sleep-apnea-insights-from-the-synairgy-trial/68963/In this episode, Patrick J. Strollo Jr, MD, FACP, FCCP, FAASM, of the University of Pittsburgh Department of Medicine, Pittsburgh, PA, discusses the data from the phase 3 SynAIRgy clinical trial for AD109, an investigational once-nightly oral treatment targeting neuromuscular dysfunction in obstructRedefining Life with Friedreich Ataxia
https://practicalneurology.com/diseases-diagnoses/neuromuscular/redefining-life-with-friedreich-ataxia/30099/We speak with neuromuscular disease expert David Lynch, MD, PhD, attending neurologist in the Division of Neurology at Children's Hospital of Philadelphia and director of the Friedreich Ataxia Program, about the emerging treatment landscape for Friedreich ataxia as well as Kiersten Riggs, who discusNMOSD Part 1 - Overview and important considerations for diagnosis
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/nmosd-part-1-overview-and-important-considerations-for-diagnosis/30086/In this series, Derrick Robertson, MD, Director of the Multiple Sclerosis Division at the University of Southern Florida discusses multiple aspects of NMOSD. Dr. Robertson is talking with us today on behalf of Horizon Therapeutics which is compensating him for his services and is sponsoring this podTavapadon Treatment for Early Parkinson Disease: Findings from the TEMPO Trials
https://practicalneurology.com/diseases-diagnoses/movement-disorders/tavapadon-treatment-for-early-parkinson-disease-findings-from-the-tempo-trials/70682/Hubert Fernandez, MD, Cleveland Clinic, Cleveland, OH, discusses findings from the TEMPO trials evaluating tavapadon, a selective dopamine D1/D5 receptor partial agonist, as monotherapy in early Parkinson disease and as an adjunct to levodopa in patients with motor fluctuations. He examines efficacyMaturing with Migraine: Practical Guidelines for Transitioning Adolescent Migraine and Headache Patients into Adult Practice
https://practicalneurology.com/diseases-diagnoses/headache-pain/maturing-with-migraine-practical-guidelines-for-transitioning-adolescent-migraine-and-headache-patients-into-adult-practice/48903/Hope O’Brien, MD, MBA, FAHS, FAAN, Founder and CEO of the Headache Center of Hope, Cincinnati, OH, discusses challenges and considerations for adult headache neurologists who are onboarding adolescent patients as they transition from pediatric practice. Dr. O’Brien highlights a framework with strateThe Consequences of Delays in the Diagnosis of Generalized Myasthenia Gravis
https://practicalneurology.com/diseases-diagnoses/neuromuscular/the-consequences-of-delays-in-the-diagnosis-of-generalized-myasthenia-gravis/39223/Delayed diagnosis of generalized myasthenia gravis is a common challenge, often leading to misdiagnosis, increased disease severity, and reduced quality of life. In this episode of NeuroFrontiers, John A. Morren, MD, FAAN, FAANEM discusses why diagnostic delays occur, how they impact patient outcomeNavigating Treatment Decisions for Individuals with Spinal Muscular Atrophy
https://practicalneurology.com/diseases-diagnoses/neuromuscular/navigating-treatment-decisions-for-individuals-with-spinal-muscular-atrophy/39222/Spinal muscular atrophy (SMA) care has shifted dramatically with the introduction of disease-modifying therapies, but how do clinicians weigh treatment options across different patient populations? In this episode of NeuroFrontiers, Charles Turck, PharmD, BCPS, BCCP, speaks with John Brandsema, MD aUpdates from the American Headache Society: Diagnostic Criteria, Preventive CGRP Therapy, and Treatment Guidance
https://practicalneurology.com/diseases-diagnoses/headache-pain/updates-from-the-american-headache-society-diagnostic-criteria-preventive-cgrp-therapy-and-treatment-guidance/37873/Jessica Ailani, MD, FAHS, FAAN, FANA, Clinical Professor of Neurology at MedStar’s Georgetown University Hospital and Director of the MedStar Georgetown Headache Center, joins Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, to review essential American Headache Society updates for migrGeneralized Myasthenia Gravis: Inside the MINT Trial and CD19 B-Cell Therapy Advances
https://practicalneurology.com/diseases-diagnoses/neuromuscular/generalized-myasthenia-gravis-inside-the-mint-trial-and-cd19-b-cell-therapy-advances/57164/Richard J. Nowak, MD, MS, Associate Professor of Neurology, Yale School of Medicine, Yale University, New Haven, CT and global principal investigator of the Myasthenia Gravis Inebilizumab Trial (MINT), discusses the phase 3 results, highlighting the safety and efficacy of CD19-targeted B-cell therapLiving with Spinal Muscular Atrophy: Genetic Testing, Therapy, and More
https://practicalneurology.com/case-reports/neuromuscular/living-with-spinal-muscular-atrophy-genetic-testing-therapy-and-more/54597/Andrew Cherico, a student at the University of Central Florida, Orlando, FL, discusses his experience living with spinal muscular atrophy (SMA), the impacts of available treatments, and how the condition intersects with his passion for sports journalism. He is joined by John W. Day, MD, PhD, Profess